Compare TransMedics Group Inc (TMDX) vs VNET Group Inc (VNET) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TransMedics Group Inc vs VNET Group Inc — how do they compare? TransMedics Group Inc trades at $79.01 (market cap $2.74B), while VNET Group Inc trades at $5.28 (market cap $1.47B). The key difference: TransMedics Group Inc is the larger of the two by market cap, and TransMedics Group Inc is trading nearer its 52-week high, VNET Group Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold TransMedics Group Inc for 24 Days and VNET Group Inc for 16 Days on average.
| TMDX | VNET | |
|---|---|---|
Market Cap | $2.74B | $1.47B |
Volume | 949,331 | 4,955,295 |
Sector | Health | Technology |
52-Week High | $150.42 | $14.03 |
52-Week Low | $61.99 | $5.13 |
Typical Hold Time | 24 Days | 16 Days |
Enterprise Value | $3.13B | $5.04B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TMDX trades at $81.07, up 0.98% today, but faces a bearish technical signal with recent price weakness. Fundamentally, the company reported strong 2025 results with $605.49M revenue and $190.29M net income, though 2026 projections show margin compression. Recent news highlights insider buying and ongoing legal investigations into fiduciary duties, creating mixed sentiment.
The stock offers potential upside to the $99.75 consensus target, supported by a 69% buy rating from analysts, but risks include earnings misses, margin pressure from heavy investment, and legal overhangs. Execution on growth amid rising costs remains critical for sustaining its premium valuation.
VNET trades at $5.39, near a 52-week low, with a bearish technical signal and negative earnings misses in recent quarters. The company reported a net loss of $256.77 million in 2025, with a negative net income margin of -22.18%, though revenue grew to $9.95 billion. Positive cash flow from operations of $1.92 billion and a strategic investment closing in September 2026 provide some operational stability amid financial challenges.
The outlook remains cautious due to persistent losses and high leverage, but analyst consensus is moderately bullish with 62.5% buy ratings. Key risks include balance sheet pressures and competitive threats in the data center market, while potential upside hinges on execution of new capacity and AI infrastructure demand.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →About VNET Group Inc
VNET Group, formerly 21Vianet, is a leading carrier-neutral data center services provider in China. It operates a dual-core strategy: a large-scale retail business serving over 7,000 enterprise customers and an aggressive wholesale segment (Hyperscale 2.0) designed to meet the high-density power and cooling demands of large-scale AI and cloud platforms.
Read more on VNET →
